Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Sage Therapeutics to Reduce Workforce by 33%, Stock Down
01:16pm, Friday, 18'th Oct 2024
SAGE announces a portfolio reprioritization plan to focus on the launch of the depression drug Zurzuvae and other pipeline developments. Stock falls in after-hours trading.
LOS ANGELES, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 28, 2024 deadline to file a lead plaintiff motion in the class action
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Sage Therapeutics Inc
11:00am, Friday, 18'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 an
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE) and certain officer
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit
12:00pm, Thursday, 17'th Oct 2024
LOS ANGELES , Oct. 17, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit agai
Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
11:00am, Thursday, 17'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage
Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.
09:47am, Thursday, 17'th Oct 2024
The biopharmaceutical company says the reorganization is meant to strengthen its balance sheet and position it for long-term growth.
Sage Therapeutics' stock lower as biotech unveils plan to cut 33% of workforce
08:14am, Thursday, 17'th Oct 2024
More than 165 jobs to go as company seeks to extend cash runway and focus on postpartum drug launch.
Sage Therapeutics to lay off more than 165 employees
07:10am, Thursday, 17'th Oct 2024
Sage Therapeutics said on Thursday it will lay off more than 165 employees or about 33% of the company's total workforce.
Shareholders of Sage Therapeutics, Inc. Should Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - SAGE
05:45am, Thursday, 17'th Oct 2024
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of SAGE during the
Sage Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAGE
04:30pm, Wednesday, 16'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 16, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed ag
Levi & Korsinsky Notifies Shareholders of Sage Therapeutics, Inc.(SAGE) of a Class Action Lawsuit and an Upcoming Deadline
12:15pm, Wednesday, 16'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 16, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE).
